- Home
- BMRA vs CYCN Comparison
BMRA vs CYCN Comparison
Compare BMRA & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRA
- CYCN
- Stock Information
- Founded
- BMRA 1971
- CYCN 2018
- Country
- BMRA United States
- CYCN United States
- Employees
- BMRA N/A
- CYCN N/A
- Industry
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- BMRA Health Care
- CYCN Health Care
- Exchange
- BMRA Nasdaq
- CYCN Nasdaq
- Market Cap
- BMRA 8.2M
- CYCN 7.6M
- IPO Year
- BMRA N/A
- CYCN N/A
- Fundamental
- Price
- BMRA $2.96
- CYCN $2.14
- Analyst Decision
- BMRA
- CYCN
- Analyst Count
- BMRA 0
- CYCN 0
- Target Price
- BMRA N/A
- CYCN N/A
- AVG Volume (30 Days)
- BMRA 250.1K
- CYCN 76.7K
- Earning Date
- BMRA 10-14-2025
- CYCN 11-13-2025
- Dividend Yield
- BMRA N/A
- CYCN N/A
- EPS Growth
- BMRA N/A
- CYCN N/A
- EPS
- BMRA N/A
- CYCN N/A
- Revenue
- BMRA $4,884,000.00
- CYCN $2,174,000.00
- Revenue This Year
- BMRA N/A
- CYCN N/A
- Revenue Next Year
- BMRA N/A
- CYCN N/A
- P/E Ratio
- BMRA N/A
- CYCN N/A
- Revenue Growth
- BMRA N/A
- CYCN N/A
- 52 Week Low
- BMRA $2.08
- CYCN $1.27
- 52 Week High
- BMRA $10.16
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- BMRA 50.63
- CYCN 39.56
- Support Level
- BMRA $2.82
- CYCN $2.03
- Resistance Level
- BMRA $3.19
- CYCN $2.46
- Average True Range (ATR)
- BMRA 0.20
- CYCN 0.14
- MACD
- BMRA 0.02
- CYCN -0.03
- Stochastic Oscillator
- BMRA 56.53
- CYCN 20.74
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.